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Interferon- -inducible protein (IP-10) belongs to the CXC
class of chemokines and plays a signiﬁcant role in the
pathophysiology of various immune and inﬂammatory
responses. It is also a potent angiostatic factor with antiﬁbrotic
properties. The biological activities of IP-10 are exerted by
interactions with the G-protein-coupled receptor CXCR3
expressed on Th1 lymphocytes. IP-10 thus forms an attractive
target for structure-based rational drug design of anti-
inﬂammatory molecules. The crystal structure of mouse
IP-10 has been determined and reveals a novel tetrameric
association. In the tetramer, two conventional CXC chemo-
kine dimers are associated through their N-terminal regions to
form a 12-stranded elongated  -sheet of  90 A ˚ in length. This
association differs signiﬁcantly from the previously studied
tetramers of human IP-10, platelet factor 4 and neutrophil-
activating peptide-2. In addition, heparin- and receptor-
binding residues were mapped on the surface of IP-10
tetramer. Two heparin-binding sites were observed on the
surface and were present at the interface of each of the two
 -sheet dimers. The structure supports the formation of higher
order oligomers of IP-10, as observed in recent in vivo studies
with mouse IP-10, which will have functional relevance.
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1. Introduction
Chemokines are involved in chemotaxis and activation of
leukocytes in immune and inﬂammatory responses by inter-
acting with their speciﬁc G-protein-coupled receptors (Moser
& Loetscher, 2001) and have been divided into C, CC, CXC
and CX3C subfamilies on the basis of their N-terminal cysteine
positions (Zlotnik & Yoshie, 2000; Ottonello, 2006).
Interferon- -inducible protein (IP-10; CXCL10; 10 kDa)
belongs to the CXC family of chemokines and is secreted by a
variety of cell types (Baggiolini et al., 1997). IP-10 acts as an
immunoinﬂammatory mediator in Th1-type inﬂammatory
diseases (Papadakis et al., 2004), rheumatoid arthritis
(Ruschpler et al., 2003), cardiac allograft rejection (Zhao et al.,
2002), multiple sclerosis (Sorensen, 2004), atherosclerosis
(Heller et al., 2006), sarcoidosis (Sugiyama et al., 2006) and
prostate cancer (Nagpal et al., 2006). The receptor for IP-10
has been recognized as CXCR3 (Loetscher et al., 1996), which
is predominantly expressed on activated T lymphocytes (Th1;
Sallusto et al., 1998) in addition to other cell types including
NK cells, dendritic cells, macrophages and B cells (Loetscher
et al., 1998; Qin et al., 1998). Two other physiological ligands
for CXCR3 are monokine induced by interferon-  (Mig;
CXCL9; Loetscher et al., 1996) and interferon-inducible T-cell
  chemoattractant (I-TAC; CXCL11; Cole et al., 1998).As a consequence of their biological and therapeutic
signiﬁcance, the three-dimensional structures of about 30
chemokines have been studied to date. More recently, the
structures of thymus and activation-regulated chemokine
(TARC; Asojo et al., 2003) from the CC chemokines and
I-TAC (Booth et al., 2004) and stroma cell-derived factor-1 
(SDF-1 ; Gozansky et al., 2005) from the CXC chemokines
have been determined. The structure of human IP-10 has been
determined previously in three different crystal forms
(Swaminathan et al., 2003). Each of these structures formed a
distinct tetrameric assembly.
Glycosaminoglycans (GAGs) are linear, highly sulfated and
heterogeneous polysaccharides that are often covalently
linked to core proteins called proteoglycans that are present
on the membrane of cells or within the extracellular matrix.
Theyhave been demonstrated to be required for the biological
function of chemokines (Yu et al., 2005) and have been shown
to facilitate their oligomerization (Vive `s et al., 2002). Binding
of chemokines to the GAG chains of cell-surface proteo-
glycans is thought to facilitate the formation of highly local-
ized concentrations of chemokines, which in turn provides
directional signals for leukocyte migration. Heparan sulfate
has been demonstrated to be required for the presentation of
chemokines on endothelial cells as well as for in vivo
recruitment of leukocytes (Wang et al., 2005).
The physiological relevance of oligomerization is still not
clear, but it has intrigued researchers to carry out studies to
understand the mechanism of the oligomerization-induced
functions of chemokines. In vivo studies with monomeric
mutants of the CC chemokines RANTES (regulated upon
activation, normal T-cell expressed and secreted), macrophage
inﬂammatory protein-1   (MIP-1  ) and monocyte chemo-
attractant protein-1 (MCP-1) showed reduced recruitment of
leukocytes (Proudfoot et al., 2003). Chemokines in monomeric
forms have also been shown to be cleared more rapidly in vivo,
suggesting a role of oligomerization in the localized retention
of chemokines (Frevert et al., 2002). More recent studies on
IP-10 mutants have clearly demonstrated the mechanism of
oligomerization-dependent recruitment of activated CD8
+ T
cells into mice airways. The monomeric mutants were unable
to induce the recruitment, although they showed signiﬁcant
receptor and heparin binding at higher concentrations in vitro.
This suggests that the oligomerization of IP-10 is essential for
its in vivo activity (Campanella et al., 2006).
Various biochemical studies and the recent discovery of its
in vivo oligomerization-dependent functions prompted us to
determine the three-dimensional structure of mouse IP-10.
Here, we present the crystal structure of mouse IP-10 at 2.5 A ˚
resolution, which shows a novel oligomeric association. The
present results provide an insight into the structural basis of
oligomerization and the physiological functions of IP-10 that
may contribute to further understanding of the structure and
function of chemokines.
2. Experimental procedures
2.1. Cloning, expression and purification
Mouse IP-10 was cloned and expressed as described by
Campanella et al. (2003) with some modiﬁcations. The
recombinant plasmid was used to transform Escherichia coli
BL21 (DE3) pLys strain and the culture was grown at 310 K.
Protein expression was induced with 0.2 mM isopropyl  -d-1-
thiogalactopyranoside. Cells were harvested 4 h after induc-
tion, pelleted and resuspended in lysis buffer containing
50 mM Tris–HCl pH 8.0 and 2 mM Na EDTA. Cells were lysed
by sonication and the cell lysate was pelleted, resuspended and
re-sonicated. 0.01% Triton X-100 was added to the cell
suspension to wash away the membrane. The pellet collected
after centrifugation at 40 000g was dissolved in solubilization
buffer containing 7 M guanidine–HCl, 0.1 M Tris–HCl pH 8.0,
0.15 M reduced glutathione and 2 mM EDTA. Refolding was
performed at 277 K following the procedure of Holloway et al.
(2001). Refolded protein was diluted ﬁvefold with MilliQ
water and applied onto an SP-Sepharose column (Fast Flow,
GE Healthcare) pre-equilibrated with 50 mM Tris–HCl,
50 mM NaCl pH 8.0. The bound fractions were eluted using a
0.05–0.75 M gradient of NaCl in 50 mM Tris–HCl buffer pH
8.0 at a ﬂow rate of 1 ml min
 1. Protein quantiﬁcation was
performed using the BCA assay (Pierce). Fractions containing
mouse IP-10 were identiﬁed by SDS–PAGE and loaded onto a
C4 RP-HPLC column pre-equilibrated with 0.1% triﬂuoro-
acetic acid in HPLC-grade water. The protein was eluted with
a linear gradient of acetonitrile containing 0.08% triﬂuoro-
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Table 1
X-ray data-collection, processing and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
PDB code 2r3z
Space group C2
Unit-cell parameters (A ˚ ,  ) a = 109.9, b = 71.5,
c = 39.6,   = 110.0
Resolution range (A ˚ ) 50.0–2.50 (2.57–2.50)
Total No. of measured reﬂections 25840
No. of unique reﬂections 9824
Completeness (%) 98.2 (89.7)
VM (A ˚ 3 Da
 1)2 . 1
No. of molecules in the ASU 4
Rmerge† (%) 9.1 (30.4)
I/ (I) 6.9 (3.2)
Rcryst‡ (%) 27.6
Rfree§ (%) 30.3
No. of protein atoms 2044
No. of water molecules 81
R.m.s. deviations
Bond lengths (A ˚ ) 0.010
Bond angles ( )1 . 4
Mean B factors (A ˚ 2)
Main-chain atoms 55.5
Side-chain atoms and waters 56.2
All atoms 56.9
Ramachandran plot
Residues in most favoured regions (%) 77.8
Residues in additionally allowed regions (%) 19.6









i IiðhklÞ, where Ii(hkl) is the observed
intensity of reﬂection i and hI(hkl)i is the average intensity of multiple observa-
tions. ‡ Rcryst =
P   jFoj j Fcj
   =
P
jFoj, where Fo and Fc are the observed and
calculated structure-factor amplitudes, respectively. § Rfree is equal to Rcryst for a
randomly selected 8% subset of reﬂections excluded from reﬁnement.acetic acid at a ﬂow rate of 1 ml min
 1. The efﬂuent was
monitored at 230 nm. Fractions containing a single band of
mouse IP-10, as identiﬁed by SDS–PAGE, were pooled and
lyophilized.
2.2. Crystallization, data collection and processing
Pure lyophilized protein was dissolved in 50 mM Tris–HCl
pH 8.0 to a concentration of 10 mg ml
 1 and crystallization
was performed by the hanging-drop vapour-diffusion method.
Initial screening produced thin plates, which were optimized
to improve the crystal quality. Diffraction-quality crystals
were ﬁnally obtained in 0.1 M Tris–HCl pH 8.0, 0.2 M CaCl2
and 35% PEG 3350 after three weeks at 289 K. A data set was
collected to 2.5 A ˚ resolution at the Synchrotron Radiation
Source (Station PX14.2), Daresbury, UK and was processed
and scaled using the programs DENZO and SCALEPACK
(Otwinowski & Minor, 1997). The crystals belong to space
group C2, with unit-cell parameters a = 109.9, b = 71.5,
c = 39.6 A ˚ ,  = 110.0 . The complete data statistics are given in
Table 1.
2.3. Structure determination and refinement
The structure of mouse IP-10 was solved by maximum-
likelihood molecular replacement using the program Phaser
(Read, 2001) from the CCP4 program suite (Collaborative
Computational Project, Number 4, 1994). The coordinates of
one molecule of human IP-10 in a truncated form (residues
9–65; PDB code 1o7y; Swaminathan et al., 2003) were used to
build the initial search model and a clear solution was
obtained in space group C2 with four molecules in the asym-
metric unit. A stacking arrangement of molecules in the unit
cell for this solution was observed in Coot (Emsley & Cowtan,
2004), which yielded no unfavourable intermolecular contacts.
Initial cycles of reﬁnement resulted in an Rcryst of 36.0% and
an Rfree of 42.9%. Iterative cycles of energy minimization,
individual B-factor reﬁnement and simulated annealing were
carried out in CNS (Bru ¨nger et al., 1998), alternated with
model building using Coot (Emsley & Cowtan, 2004). Resi-
dues were replaced according to the amino-acid sequence of
mouse IP-10. The positions of 81 water molecules were iden-
tiﬁed from the |Fo|   |Fc| electron-density maps above 3  and
were checked manually for their interactions with protein
atoms. The missing residues at the N- and C-termini were
added as their density appeared with progressive reﬁnement.
Reﬁnement was stopped when no further improvement in
Rfree was made. The ﬁnal model has an Rcryst of 27.6% and an
Rfree of 30.3%. Crystallographic statistics are given in Table 1.
Figures were produced using the programs PyMOL (DeLano
Scientiﬁc LLC; http://www.pymol.org) and POV-Ray (http://
www.povray.org).
3. Results and discussion
3.1. Quality of the structure
The structure of mouse IP-10 has been determined at 2.5 A ˚
resolution. The ﬁnal model contains four molecules in the
asymmetric unit: A (residues 1–68), B (residues 1–67), C
(residues 4–68) and D (residues 4–67). Electron density for the
ﬁrst three N-terminal residues could not be observed in
molecules C and D, whereas density for C-terminal residues
beyond 67 (in molecules B and D) and 68 (in molecules A and
C) could not be observed. Some disorder was observed at the
C-terminal ends, thus affecting the length of the C-terminal
helices. However, the C-terminal residues were not found to
interact directly with heparin and CXCR3 (Campanella et al.,
2003) and hence the absence of these residues did not affect
our analysis. There are no breaks in the main chain and most
of the side chains are located in density. Some residues at the
surface show disorder or more than one conformation. The
structure has good geometry, with root-mean-square (r.m.s.)
deviations of 0.010 A ˚ and 1.4  in bond lengths and bond
angles, respectively. The Ramachandran plot (Ramachandran
& Sasisekharan, 1968) obtained using PROCHECK (Las-
kowski et al., 1993) showed that 77.8% of residues fall in most
favoured regions, whereas 19.6% and 2.6% were in addition-
ally and generously allowed regions, respectively. The reﬁne-
ment statistics are given in Table 1.
3.2. The mouse IP-10 structure
The structure of mouse IP-10 contains four molecules in the
asymmetric unit. Each molecule exhibits the typical chemo-
kine structural fold consisting of an extended N-terminal loop,
three antiparallel  -strands and a C-terminal helix lying
obliquely across the  -sheet (Fig. 1a). All the molecules have a
similar core structure, with differences in the N- and C-termini
and loop regions. Superposition of the C
  atoms of the four
molecules shows an r.m.s. deviation of 0.5–1.07 A ˚ . In each
molecule, the N-terminal extended loop is stabilized by two
disulﬁde bonds between conserved cysteines (9:36 and 11:53).
A dimer is formed by molecules A and D, which are related by
pseudosymmetry. Molecules B and C form a similar pseudo-
symmetrical dimer (Fig. 1b). In each of the two dimers, the  1
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Figure 1
(a) Monomeric structure of mouse IP-10. The three  -strands and
 -helices are labelled. The N- and C-termini are indicated. The disulﬁde
bonds stabilizing the N-terminal extended loop are shown in ball-and-
stick representation. (b) Ribbon diagram of the pseudosymmetrical
dimer formed between molecules B (pink) and C (green), consisting of a
six-stranded  -sheet with two antiparallel  -helices. Molecules A and D
form a similar dimer.strands from each monomer associate to form a six-stranded
 -sheet with two antiparallel  -helices lying on one face of the
 -sheet. This structural organization is similar to the dimeric
CXC chemokine structures. The two dimers have an r.m.s.d of
0.59 A ˚ (122 C
  atoms). The C
  backbones of the pseudo-
symmetrical dimers in the present structure deviate by an
average of 1.17 A ˚ (r.m.s.) from human IP-10 dimers (PDB
codes 1o7y, 1o7z, 1o80; Swaminathan et al., 2003), while they
show a C
  r.m.s. deviation of 1.4–1.6 A ˚ compared with the
dimers formed by interleukin-8 (IL-8; PDB code 3il8; Baldwin
et al., 1991), platelet factor 4 (PF4; PDB code 1rhp; Zhang et
al., 1994), neutrophil-activating peptide-2 (NAP-2; PDB code
1nap; Malkowski et al., 1995), growth-related oncogene- 
(Gro ; PDB code 1qnk; Qian et al., 1999) and SDF-1  (PDB
code 1a15; Gozansky et al., 2005) from the CXC family.
The dimers (A–D and B–C) are primarily stabilized by
reciprocal interactions between opposing  1 strands. The
main-chain hydrogen bonding at the interface is limited to
reciprocal interactions between residues Leu27 and Ile29
(thus accounting for four hydrogen bonds) owing to the
presence of Pro31, which disrupts the  -structure. Similar
interactions were observed in human IP-10 dimers owing to
the conserved Pro31. However, in other CXC chemokines this
position is occupied by residues other than Pro and hence four
residues are involved in main-chain reciprocal interactions
compared with two in the IP-10 structures. Additional inter-
actions at the interface are contributed by salt bridges
between residues Lys26 and Glu28 of the  1 strands from both
the molecules in addition to extensive van der Waals contacts.
The involvement of the C-terminal helices in the inter-
molecular interactions is limited owing to their short lengths
and consists of two hydrogen bonds between residues
Lys62 N
  and Lys66 N
  of molecule B with Phe68 O and
Ala67 O of molecule C, respectively. The ionic interactions at
the C-terminal regions are absent in molecules A and D and
only van der Waals contacts are made (Table 2, Fig. 2). The
interfaces between A and D and between B and C bury 1280
and 1170 A ˚ 2 of solvent-accessible surface area, respectively,
which is comparable to the buried surface areas of other CXC
chemokine dimers.
3.3. Mouse IP-10 tetramer
In addition to the A–D and B–C dimers, another dimer is
formed between molecules A and B in the mouse IP-10
structure. This results in a distinct tetrameric assembly that is
formed by the association of two pseudosymmetrical dimers:
A–D and B–C (Fig. 3). The tetramer has an elongated struc-
ture with approximate dimensions of 90   40 A ˚ 2. Inter-
molecular contacts in the tetramer are through molecules A
and B. The two molecules associate through their N-terminal
loops in an antiparallel fashion such that their  -helices lie on
one face of the  -strands, while the interacting N-terminal
loops are on the back of the strands. The rotation axis parallel
to the  -sheets and dissecting the A–B dimer relates chains A
and B with a rotation angle of 179.1 ,a s
calculated by LSQMAN (Kleywegt & Jones,
1994). This is a novel association in which
the tetramer consists of two six-stranded
antiparallel  -sheets, with an antiparallel
sheet formed by the N-terminal regions
between the two six-stranded  -sheets and
all four helices lying on one face of the  -
sheet (Fig. 4). This type of association differs
signiﬁcantly from many of the chemokine
oligomeric structures studied to date. Inter-
molecular association through N-terminal
regions has been observed previously in CC
chemokines such as MIP-1  (Lodi et al.,
1994) and RANTES (Shaw et al., 2004).
However, these dimeric structures differ
considerably from the A–B dimer in the
research papers
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Table 2
Hydrogen bonds between the A–B, A–D and B–C dimers.
Hydrogen bonds were calculated with the program HBPLUS (McDonald &
Thornton, 1994).
(a) A–B interface.
Molecule A Molecule B Distance (A ˚ )
Val7 N Val7 O 2.80
Val7 O Val7 N 2.65
Arg8 N
" Ala4 O 3.11
Ile14 O Asn55 N
 2 2.74
Asp16 O
 2 Asn55 N
 2 3.14
Arg38 N
" Ile12 O 3.15
Asn55 N
 2 Ile14 O 3.09
(b) A–D/B–C interface.
Molecule A (B) Molecule D (C) Distance† (A ˚ )
Lys26 N
  Glu28 O
"1 3.35 (2.87)
Leu27 N Ile29 O 3.35 (3.03)
Leu27 O Ile29 N 3.12 (2.85)
Glu28 O
"1 Lys26 N
  3.42 (3.27)
Ile29 N Leu27 O 2.92 (3.05)
Ile29 O Leu27 N 2.99 (3.10)
Lys62 N
  Phe68 O — (3.21)
Lys66 N
  Ala67 O — (3.25)
† Values in parentheses are for the B–C dimer.
Figure 2
Stereoview of the intermolecular interactions at the B–C interface. Residues from molecules B
and C are shown in pink and green, respectively. Similar interactions between the  1 strands
were observed at the A–D interface.present structure. In these CC chemokines, two monomers
associate together such that their three-stranded  -sheets face
each other with a short  -sheet formed by the interacting
N-terminal regions in the centre. The C-terminal helix of each
of the monomer lies on the exterior face of the  -sheet.
The A–B dimer is primarily stabilized by the reciprocal
main-chain hydrogen bonds between the two N-terminal
loops. However, the extended N-terminal loop of one mole-
cule also interacts with the 30s loop and 50s loop of other
molecule in a reciprocal manner such that a total of seven
hydrogen bonds are formed at the A–B interface (Fig. 4,
Table 2). In addition to these hydrogen bonds, the two
molecules have an extensive network of hydrophobic inter-
actions. The solvent-accessible area at the interface in the
dimer is reduced by 1770 A ˚ 2, which is higher than the buried
surface area of the pseudosymmetrical dimers A–D and B–C
(1280 and 1170 A ˚ 2, respectively).
The mouse IP-10 structure differs signiﬁcantly in its tetra-
meric association from human IP-10 structures. The human
IP-10 tetramer in the monoclinic space group (M form) is
formed by the association of two pseudosymmetrical dimers
such that the two six-stranded  -sheets face each other while
the C-terminal helices are present on the exterior. This
arrangement of subunits is similar to the tetramers of the CXC
chemokines PF4 (Zhang et al., 1994) and NAP-2 (Malkowski
et al., 1995) (Fig. 5). In the tetragonal (T form) and hexagonal
(H form) space groups, the human IP-10 dimers associate with
the symmetry-related dimers through their  3 strands to form
a 12-stranded antiparallel  -sheet structure that has a sharp
kink in the middle which gives an open barrel-shaped struc-
ture to the complex. However, in the H-form tetramer, the
dimers also form N-terminal asymmetric interactions, thus
bringing the chains closer (Swaminathan et al., 2003). The
crystal packing of the human IP-10 structures in all three space
groups show different arrangements of molecules compared
with the mouse IP-10 structure. In contrast to the mouse IP-10
structure, which has an elongated cylindrical shape, all these
tetramers form globular-shaped structures (Fig. 5).
3.4. Glycosaminoglycan-binding regions
Glycosaminoglycans (GAGs) on cells bearing chemokine
receptors have been reported to facilitate chemokine–
receptor interactions (Hoogewerf et al., 1997). The heparin-
binding residues of mouse IP-10 were determined by
side-directed mutagenesis. The mutational analysis indicated
residues Arg20, Arg22, Ile24, Lys26, Lys46 and Lys47 to be
potentially involved in heparin binding (Campanella et al.,
2003). Arg22 and Lys46 were found to be critical for binding;
these residues are conserved and also form the heparin-
binding site in human IP-10 (Swaminathan et al., 2003) and
PF4 (Mayo et al., 1995). Single- and double-point mutations in
the C-terminal helix did not affect heparin binding. However,
the mutation of four basic residues at the C-terminus to
neutral and acidic residues resulted in reduced heparin
binding (Campanella et al., 2003). The reduced heparin
binding arising from these mutations is likely to be the
consequence of an electrostatic effect (Campanella et al.,
2003). The heparin-binding residues are present at the N-loop/
 1 strand and  2 strand/40s loop junctions in the IP-10
structure. In the pseudosymmetrical dimer A–D (or B–C),
these residues co-localize to form a basic cluster that lines a
groove that is present on the dimeric
interface along the  1 strands. Associa-
tion of the two pseudosymmetrical
dimers, with each dimer having one
binding site, results in the presence of
two putative heparin-binding sites per
tetramer. Both binding sites lie on one
face of the tetramer, opposite to the
helices, running along the  1 strands
and extending across the edges, thus
representing maximal possible interac-
tions with the heparin (Fig. 6a).
The potential heparin-binding resi-
dues in human IP-10 were identiﬁed as
Arg22, Lys46, Lys47, Lys48, Lys62 and
Lys66 (Swaminathan et al., 2003), which
partially overlap with the mouse IP-10
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Figure 3
Schematic representation of the mouse IP-10 structure. The tetramer is
formed by the association of dimers B–C (shown in pink and green) and
A–D (shown in blue and grey).
Figure 4
Stereo representation of the hydrogen bonds formed at the A–B interface. Residues from molecule
A are shown in blue and those from molecule B in pink.heparin-binding site. In the human IP-10 (M form) and PF4
structures, the heparin-binding residues form a ring around
the tetramers, which follows a scattered and convoluted path
in the tetramers of the T and H forms of human IP-10. In all
these structures, the C-terminal helices are involved in the
dimeric interface such that the binding site runs perpendicular
to the C-terminal helices, with residues from the loop
connecting the N-terminal region and the  1 strand forming
the extended edges. Hence, the association of the dimers
might form two binding sites per tetramer, similar to those
research papers
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Figure 5
Backbone tracing of the oligomeric structures formed in mouse and human IP-10, platelet factor 4 and neutrophil-activating peptide-2. Four chains are
shown in each structure, in which a typical chemokine dimer is formed between the green and magenta chains and the blue and grey chains, respectively.
Note the different association of dimers in each structure. This ﬁgure was drawn using the program SwissPDBViewer (Guex & Peitsch, 1997).
Figure 6
(a) Surface representation of the heparin-binding residues (shown in green) in the mouse IP-10 structure. The views are related by a 180  rotation about
the y axis (the lower view is identical to that in Fig. 3). (b) The receptor-binding regions on the surface of the monomeric form of IP-10. Arg5 and Arg8
are shown in blue, Arg20, Arg22 and Ile24 in yellow and Lys46 and Lys47 in cyan. Two views are shown that are related by a rotation of 180  about the y
axis. (c) The mapping of receptor-binding regions on the mouse IP-10 tetramer. The two views are related by a 180  rotation about the y axis (the lower
view is the same as that in Fig. 3).observed in mouse IP-10. Heparin–chemokine structural
modelling studies indeed showed two heparin oligosacchar-
ides docked onto the PF4 tetramer, each oligosaccharide
adopting a curved shape that runs across the pseudosymme-
trical dimer perpendicular to the  -helices and bridges the two
dimers (Lortat-Jacob et al., 2002). However, the previously
modelled SDF-1 –heparin complex shows the oligosaccharide
binding to the dimer along the interface between the  1
strands, with the  -helices lying on the opposite face (Sadir et
al., 2001). The oligosaccharide thus adopts a straight and
extended shape. More recently, the crystal structure of SDF-
1  in complex with heparin disaccharide revealed two binding
sites, one of which is present at the dimer interface, thus
supporting the previous studies (Murphy et al., 2007). The
mouse IP-10 structure analysis indicates that the heparin
oligosaccharide may bind to the IP-10 dimer in a similar
fashion to that observed in SDF-1 . GAGs have been shown
to induce chemokine oligomerization, thus forming a chemo-
kine gradient (Proudfoot, 2006). In addition to chemokine
presentation to the receptors, GAGs may play an active role in
the chemokine function. For example, RANTES in complex
with GAGs has been shown to have anti-HIVactivity (Burns
et al., 1999). Further studies are required to understand the
modulation of chemokine activity by GAGs.
3.5. CXCR3-binding regions
IP-10-induced physiological functions are mediated by the
binding of IP-10 to cell-surface CXCR3. Mutagenesis studies
of mouse IP-10 identiﬁed the residues that are involved in
binding to the receptor (Campanella et al., 2003). Residues in
the 20s loop (Arg20, Arg22),  1 strand (Ile24) and 40s loop
(Lys46 and Lys47) were found to be important for receptor
binding. The N-terminal residues preceding the ﬁrst cysteine,
speciﬁcally Arg5 and Arg8, were found to be involved but not
critical for receptor binding. However, Arg8 was found to be
critical for CXCR3-mediated signalling. Arg8 and Lys46 are
conserved in the human and mouse CXCR3 ligands. Single
and double mutations in the C-terminal helix did not affect
receptor binding (Campanella et al., 2003). The CXCR3-
binding site partially overlapped with the heparin-binding site,
which further indicates that heparin may play an active role in
the biological function of mouse IP-10. Fig. 6(b) shows the
regions involved in receptor binding in the IP-10 monomeric
structure. The receptor-binding regions are preserved when
mapped onto the surface of the tetramer (Fig. 6c), indicating
that the oligomerization of IP-10 may not affect its receptor
binding. In human IP-10, immunological studies indicated
residues 20–36 to be involved in CXCR3 binding, which also
overlaps with the receptor-binding residues of mouse IP-10.
Oligomerization has been demonstrated to be an essential
requirement for the biological function of IP-10 (Campanella
et al., 2006). Cytokine receptors have been reported to
undergo dimerization upon cytokine binding (Rodriguez-
Frade et al., 1999). The CXC chemokine SDF1-  has been
reported to induce dimerization of the CXCR4 receptor upon
binding (Vila-Coro et al., 1999). Receptor clustering is known
to occur during the initiation of ligand-induced internalization
in triggering the biological responses. However, receptor
clustering has not yet been reported for CXCR3 molecules.
3.6. Biological significance of oligomerization
IP-10 has been shown to exist as higher order oligomeric
forms under physiological conditions (Campanella et al.,
2006). However, N-methylated Leu27 monomeric mutants of
IP-10 had reduced heparin and CXCR3 binding but were able
to induce CXCR3 internalization and chemotaxis of CD8
+ T
cells expressing CXCR3 at tenfold higher concentrations than
wild-type IP-10 in vitro. However, the monomeric mutants
failed to induce in vivo recruitment of activated CD8
+ T cells.
Oligomerization, rather than heparin and CXCR3 binding,
was found to be essential for in vivo recruitment of T cells
(Campanella et al., 2006). In the IP-10 structure, Leu27 is
present in the  1 strand and is involved in reciprocal main-
chain hydrogen bonds with Ile29 of the other monomer
forming the antiparallel dimer A–D (or B–C). The presence of
the N-methyl group disrupts this interaction and thus prevents
the formation of dimers and possibly higher order complexes.
Only oligomeric forms of IP-10 were able to bind to endo-
thelial and epithelial cells in a GAG-dependent manner. The
binding of oligomeric IP-10 to endothelial cells was shown to
be required for the transendothelial migration of CXCR3-
expressing lymphocytes. The binding creates a haptotactic
gradient, thus inducing the recruitment of activated T cells
(Campanella et al., 2006). Oligomerization is therefore
important for the activity of IP-10.
4. Conclusion
The mouse IP-10 structure presents a novel tetramer in which
two typical CXC chemokine dimers associate through their
N-terminal regions to form a tetrameric assembly. Moreover,
the free N-terminal regions of two molecules at opposite ends
of the tetramer increase the possibility of further association
of molecules to form higher order oligomers. The presence of
multiple heparin-binding sites on IP-10 oligomers might play a
role in the structural stabilization of oligomers together with a
role in the binding of oligomers to endothelial cells to induce
the recruitment of CXCR3-expressing T cells. The cell-bound
GAGs may also induce IP-10 oligomerization on the cell
surface. The present study contributes to the existence of IP-
10 in different oligomeric forms which is important for its in
vivo activity. Both mouse and human IP-10 form similar
dimers, interacting though their  1 strands, as observed for
other CXC chemokines. However, the heparin- and CXCR3-
binding sites in human and mouse IP-10 only partially overlap.
Both the structures present two heparin-binding sites per
tetramer and the receptor-binding sites are preserved on the
tetrameric surfaces. Investigation of the physiological signiﬁ-
cance of oligomerization is currently under way. In addition,
structural studies of IP-10 in complex with GAGs will be
required in order to differentiate GAG-mediated and GAG-
independent oligomerization and their functional relevance.
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was not directly involved in binding to both heparin and
CXCR3, structural studies of IP-10 in complex with heparin
and CXCR3 are required in order to establish the role of the
C-terminal helix in binding and its importance in chemokine
function.
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